The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday, July 25, transferred an appeal over an award issued in an ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Alkermes today and set a price target of $42.00. The company’s shares opened today at $28.98. Take advantage of TipRanks Premium at 50% ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...